Go Pro
→ Feds Say Your Cash Isn’t Property—Can They Take It? (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunome, Inc. stock logo
IMNM
Immunome
$26.89
+0.5%		$25.08
$8.66
▼
$30.06
$3.06B2.131.35 million shs424,241 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$78.74
-0.6%		$77.86
$40.00
▼
$99.50
$301.60M0.97563,441 shs140,403 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.95
-1.8%		$29.51
$23.05
▼
$42.21
$2.98B0.091.04 million shs2.28 million shs
NantKwest, Inc. stock logo
NK
NantKwest
$6.98
+1.7%		$28.01
$2.52
▼
$45.42
$763.23M2.611.57 million shs16.54 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunome, Inc. stock logo
IMNM
Immunome
0.00%-2.37%+6.91%+45.51%+154.37%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%+0.74%+2.31%+15.94%+30.40%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+0.24%-9.16%-16.39%-5.93%
NantKwest, Inc. stock logo
NK
NantKwest
0.00%0.00%0.00%0.00%+190.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Immunome, Inc. stock logo
IMNM
Immunome
$26.89
+0.5%		$25.08
$8.66
▼
$30.06
$3.06B2.131.35 million shs424,241 shs
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
$78.74
-0.6%		$77.86
$40.00
▼
$99.50
$301.60M0.97563,441 shs140,403 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$24.95
-1.8%		$29.51
$23.05
▼
$42.21
$2.98B0.091.04 million shs2.28 million shs
NantKwest, Inc. stock logo
NK
NantKwest
$6.98
+1.7%		$28.01
$2.52
▼
$45.42
$763.23M2.611.57 million shs16.54 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Immunome, Inc. stock logo
IMNM
Immunome
0.00%-2.37%+6.91%+45.51%+154.37%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.00%+0.74%+2.31%+15.94%+30.40%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
0.00%+0.24%-9.16%-16.39%-5.93%
NantKwest, Inc. stock logo
NK
NantKwest
0.00%0.00%0.00%0.00%+190.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Immunome, Inc. stock logo
IMNM
Immunome
2.85
Moderate Buy$34.6428.70% Upside
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
2.75
Moderate Buy$107.7038.41% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.85
Moderate Buy$49.7398.69% Upside
NantKwest, Inc. stock logo
NK
NantKwest
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NK, IRON, IMNM, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$52.00
9/2/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$88.00 ➝ $100.00
9/1/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
8/17/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$90.00
8/12/2026
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$31.00 ➝ $35.00
8/12/2026
Immunome, Inc. stock logo
IMNM
Immunome
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$37.00 ➝ $38.00
8/6/2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$118.00 ➝ $120.00
8/6/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$51.00 ➝ $50.00
7/21/2026
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$31.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$58.00
7/20/2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Immunome, Inc. stock logo
IMNM
Immunome
$6.94M440.44N/AN/A$5.75 per share4.68
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/A$19.52 per shareN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$22.50M132.97N/AN/A$5.97 per share4.19
NantKwest, Inc. stock logo
NK
NantKwest
$40K19,080.70N/AN/A$1.23 per share5.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Immunome, Inc. stock logo
IMNM
Immunome
-$212.39M-$2.53N/AN/AN/AN/A-50.56%-46.93%11/5/2026 (Estimated)
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$212.18M-$6.58N/AN/AN/AN/A-37.17%-33.65%11/5/2026 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$203.82M-$2.16N/AN/AN/A-3,644.21%-34.81%-31.50%11/4/2026 (Estimated)
NantKwest, Inc. stock logo
NK
NantKwest
-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/A

Latest NK, IRON, IMNM, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Immunome, Inc. stock logo
IMNM
Immunome
-$0.5138-$0.65-$0.1362-$0.65$0.17 millionN/A
8/5/2026Q2 2026
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.4819-$0.52-$0.0381-$0.52$2.83 million$3.70 million
7/30/2026Q2 2026
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
-$1.71-$1.54+$0.17-$1.54$1.00 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
NantKwest, Inc. stock logo
NK
NantKwest
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Immunome, Inc. stock logo
IMNM
Immunome
N/A
15.08
15.08
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
0.09
24.14
24.14
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
9.03
9.03
NantKwest, Inc. stock logo
NK
NantKwest
N/A
4.74
4.74

Institutional Ownership

CompanyInstitutional Ownership
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
83.70%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
NantKwest, Inc. stock logo
NK
NantKwest
9.38%

Insider Ownership

CompanyInsider Ownership
Immunome, Inc. stock logo
IMNM
Immunome
7.21%
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
3.76%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
12.74%
NantKwest, Inc. stock logo
NK
NantKwest
71.73%
CompanyEmployeesShares OutstandingFree FloatOptionable
Immunome, Inc. stock logo
IMNM
Immunome
40113.58 million105.39 millionOptionable
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
303.83 million3.69 millionNot Optionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4119.54 million104.31 millionOptionable
NantKwest, Inc. stock logo
NK
NantKwest
160109.35 millionN/ANot Optionable

Recent News About These Companies

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294926/0/en/gt-biopharma-announces-first-patient-dosed-in-phase-1-trial-of-gtb-5550-a-b7-h3-targeted-natural-killer-nk-cell-engager-for-solid-tumors.html
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
September 4, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34577337/nk-cell-therapy-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies/
Piper Sandler Upgrades ImmunityBio (IBRX)
May 21, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/piper-sandler-upgrades-immunitybio-ibrx/ar-AA1Fb7J5
HC Wainwright & Co. Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
March 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-co-initiates-coverage-of-immunitybio-ibrx-with-buy-recommendation/ar-AA1AoIt5
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger Treatments
February 4, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4754373-aardvark-therapeutics-starts-100-million-ipo-effort-for-hunger-treatments
BTIG Initiates Coverage of ImmunityBio (IBRX) with Buy Recommendation
January 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/btig-initiates-coverage-of-immunitybio-ibrx-with-buy-recommendation/ar-BB1rgp8f
Northern Knights Cricket Team
August 3, 2024  |  espncricinfo.comE
Natural Killer Cells Therapeutics Market Projections: Anticipated Trends and Developments
May 27, 2024  |  taiwannews.com.twT
From Culture to Clinic: Scale Up NK Cell Expansion
May 1, 2024  |  the-scientist.comT
P!nk puts on showstopping performance for first TSV show
March 25, 2024  |  townsvillebulletin.com.auT
Space NK Promo Code - Up to £330 off
March 16, 2024  |  glamourmagazine.co.ukG
Space Nk Promo Codes
February 4, 2024  |  time.comT
NK Industries Ltd.
December 12, 2023  |  ndtv.comN
NK Gupta
November 28, 2023  |  hindustantimes.comH
P!NK's concert in Phoenix: Acrobatic spectacle, raw emotion and Brandi Carlile's last stop
October 23, 2023  |  azcentral.comA
P!NK's 2023 tour setlist: 'Who Knew,' 'So What' and every song she sang in Phoenix
October 18, 2023  |  azcentral.comA
Space NK beauty advent calendar 2023 early access waitlist now open
September 15, 2023  |  thesun.co.ukhttps://www.thesun.co.uk/shopping/15697374/space-nk-advent-calendar/
Frankie Bridge shares her new Space NK beauty buys including concealer people 'love'
August 13, 2023  |  mirror.co.ukM
Lost metabolic fitness of CAR NK cells is key mechanism of tumor resistance, study discovers
August 3, 2023  |  medicalxpress.comM
Formation and function of the lytic NK-cell immunological synapse
July 9, 2023  |  nature.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laptop displaying a candlestick stock price chart on a desk with autumn leaves and the word September overlaid.
5 Stocks to Buy in September Before Wall Street Catches On
By Thomas Hughes | August 26, 2026
Magnifying glass highlighting glowing candlestick chart bars against a dark background with an upward trending stock price line.
3 Overlooked Stocks Analysts Still Like as AI Trades Get Crowded
By Nathan Reiff | August 11, 2026
Illuminated Pathward logo displayed on a wall in a corporate office reception area with glass doors.
Pathward’s Credit Scare Tests Its Comeback Story
By Peter Frank | August 25, 2026
A dark green Rivian electric pickup truck parked in front of a building displaying the Rivian logo, with mountains in the background.
What Rising Delivery Forecasts Say About Rivian's Stock Prospects
By Sam Quirke | August 24, 2026
Snowflake logo displayed on illuminated wall in a data center setting with server racks visible.
Snowflake Could Be Headed for New Highs Despite Insider Selling
By Thomas Hughes | August 24, 2026
Immunome stock logo

Immunome NASDAQ:IMNM

$26.88 +0.13 (+0.47%)
As of 02:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Disc Medicine stock logo

Disc Medicine NASDAQ:IRON

$78.74 -0.50 (-0.62%)
As of 02:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$24.95 -0.45 (-1.77%)
As of 02:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

NantKwest stock logo

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas